atai Life Sciences to Collaborate with Massachusetts General Hospital to Accelerate Discovery of Mechanisms Underlying Therapeutic Effects of Psychedelic Agents

Articles | January 26, 2021

atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced it has entered into a collaboration with Massachusetts General Hospital and its new initiative, the Center for Neuroscience of Psychedelics, to advance novel… Read More

atai Life Sciences Acquires Majority Stake in Recognify Life Sciences to Develop Novel Treatment for Cognitive Impairment Associated with Schizophrenia

Articles | January 12, 2021

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has acquired a majority stake in Recognify Life Sciences, an entity developing a treatment for Cognitive Impairment associated with Schizophrenia (CIAS). Recognify’s lead compound, “RL-007”,… Read More

atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer

Articles | December 16, 2020

atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced the appointment of Greg Weaver as Chief Financial Officer (CFO) and Rolando Gutierrez-Esteinou as Chief Medical Officer (CMO). Read More